9 results on '"Klein, Reinhild"'
Search Results
2. Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium.
- Author
-
Cabral-Marques O, Moll G, Catar R, Preuß B, Bankamp L, Pecher AC, Henes J, Klein R, Kamalanathan AS, Akbarzadeh R, van Oostveen W, Hohberger B, Endres M, Koolmoes B, Levarht N, Postma R, van Duinen V, van Zonneveld AJ, de Vries-Bouwstra J, Fehres C, Tran F, do Vale FYN, da Silva Souza KB, Filgueiras IS, Schimke LF, Baiocchi GC, de Miranda GC, da Fonseca DLM, Freire PP, Hackel AM, Grasshoff H, Stähle A, Müller A, Dechend R, Yu X, Petersen F, Sotzny F, Sakmar TP, Ochs HD, Schulze-Forster K, Heidecke H, Scheibenbogen C, Shoenfeld Y, and Riemekasten G
- Subjects
- Humans, Autoantibodies, Autoimmunity, Receptors, G-Protein-Coupled metabolism, COVID-19, Autoimmune Diseases
- Abstract
G protein-coupled receptors (GPCR) are involved in various physiological and pathophysiological processes. Functional autoantibodies targeting GPCRs have been associated with multiple disease manifestations in this context. Here we summarize and discuss the relevant findings and concepts presented in the biennial International Meeting on autoantibodies targeting GPCRs (the 4th Symposium), held in Lübeck, Germany, 15-16 September 2022. The symposium focused on the current knowledge of these autoantibodies' role in various diseases, such as cardiovascular, renal, infectious (COVID-19), and autoimmune diseases (e.g., systemic sclerosis and systemic lupus erythematosus). Beyond their association with disease phenotypes, intense research related to the mechanistic action of these autoantibodies on immune regulation and pathogenesis has been developed, underscoring the role of autoantibodies targeting GPCRs on disease outcomes and etiopathogenesis. The observation repeatedly highlighted that autoantibodies targeting GPCRs could also be present in healthy individuals, suggesting that anti-GPCR autoantibodies play a physiologic role in modeling the course of diseases. Since numerous therapies targeting GPCRs have been developed, including small molecules and monoclonal antibodies designed for treating cancer, infections, metabolic disorders, or inflammatory conditions, anti-GPCR autoantibodies themselves can serve as therapeutic targets to reduce patients' morbidity and mortality, representing a new area for the development of novel therapeutic interventions., (Copyright © 2023. Published by Elsevier B.V.)
- Published
- 2023
- Full Text
- View/download PDF
3. Recurrent SARS-CoV-2 Infection and Impaired Immunologic Response in a Pediatric Oncologic Patient While Treated With Radiochemotherapy.
- Author
-
Eichholz T, Arendt AM, Holzer U, Seitz C, Rabsteyn A, Ganzenmueller T, Klein R, Walz J, and Lang P
- Subjects
- Antibodies, Viral, Chemoradiotherapy, Child, Humans, SARS-CoV-2, T-Lymphocytes, COVID-19
- Abstract
Immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pediatric patients with malignant disease may be affected by tumor therapy. Here, we report the case of a child with rhabdomyosarcoma and recurrent SARS-CoV-2 infection. Immunologic responses, analyzed by T-cell activity and anti-viral IgG levels, were impaired and not durable as a result of intensive radiochemotherapy., Competing Interests: J.W. is listed as inventor for patents on peptides described in this manuscript. The other authors have no conflicts of interest to disclose., (Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2022
- Full Text
- View/download PDF
4. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity.
- Author
-
Heitmann JS, Bilich T, Tandler C, Nelde A, Maringer Y, Marconato M, Reusch J, Jäger S, Denk M, Richter M, Anton L, Weber LM, Roerden M, Bauer J, Rieth J, Wacker M, Hörber S, Peter A, Meisner C, Fischer I, Löffler MW, Karbach J, Jäger E, Klein R, Rammensee HG, Salih HR, and Walz JS
- Subjects
- Administration, Cutaneous, Adolescent, Adult, Aged, Aged, 80 and over, CD8-Positive T-Lymphocytes immunology, COVID-19 prevention & control, COVID-19 virology, COVID-19 Vaccines administration & dosage, COVID-19 Vaccines adverse effects, Clinical Trials, Phase II as Topic, Female, Granuloma immunology, Humans, Immunogenicity, Vaccine, Interferon-gamma immunology, Male, Middle Aged, T-Lymphocytes, Helper-Inducer immunology, Vaccines, Subunit administration & dosage, Vaccines, Subunit adverse effects, Young Adult, COVID-19 immunology, COVID-19 Vaccines immunology, SARS-CoV-2 immunology, T-Lymphocytes immunology, Vaccines, Subunit immunology
- Abstract
T cell immunity is central for the control of viral infections. CoVac-1 is a peptide-based vaccine candidate, composed of SARS-CoV-2 T cell epitopes derived from various viral proteins
1,2 , combined with the Toll-like receptor 1/2 agonist XS15 emulsified in Montanide ISA51 VG, aiming to induce profound SARS-CoV-2 T cell immunity to combat COVID-19. Here we conducted a phase I open-label trial, recruiting 36 participants aged 18-80 years, who received a single subcutaneous CoVac-1 vaccination. The primary end point was safety analysed until day 56. Immunogenicity in terms of CoVac-1-induced T cell response was analysed as the main secondary end point until day 28 and in the follow-up until month 3. No serious adverse events and no grade 4 adverse events were observed. Expected local granuloma formation was observed in all study participants, whereas systemic reactogenicity was absent or mild. SARS-CoV-2-specific T cell responses targeting multiple vaccine peptides were induced in all study participants, mediated by multifunctional T helper 1 CD4+ and CD8+ T cells. CoVac-1-induced IFNγ T cell responses persisted in the follow-up analyses and surpassed those detected after SARS-CoV-2 infection as well as after vaccination with approved vaccines. Furthermore, vaccine-induced T cell responses were unaffected by current SARS-CoV-2 variants of concern. Together, CoVac-1 showed a favourable safety profile and induced broad, potent and variant of concern-independent T cell responses, supporting the presently ongoing evaluation in a phase II trial for patients with B cell or antibody deficiency., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
5. Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer.
- Author
-
Bilich T, Roerden M, Maringer Y, Nelde A, Heitmann JS, Dubbelaar ML, Peter A, Hörber S, Bauer J, Rieth J, Wacker M, Berner F, Flatz L, Held S, Brossart P, Märklin M, Wagner P, Erne E, Klein R, Rammensee HG, Salih HR, and Walz JS
- Subjects
- CD4-Positive T-Lymphocytes, Humans, Immunity, Programmed Cell Death 1 Receptor, SARS-CoV-2, COVID-19, Neoplasms
- Abstract
Patients with cancer, in particular patients with hematologic malignancies, are at increased risk for critical illness upon COVID-19. We here assessed antibody as well as CD4
+ and CD8+ T-cell responses in unexposed and SARS-CoV-2-infected patients with cancer to characterize SARS-CoV-2 immunity and to identify immunologic parameters contributing to COVID-19 outcome. Unexposed patients with hematologic malignancies presented with reduced prevalence of preexisting SARS-CoV-2 cross-reactive CD4+ T-cell responses and signs of T-cell exhaustion compared with patients with solid tumors and healthy volunteers. Whereas SARS-CoV-2 antibody responses did not differ between patients with COVID-19 and cancer and healthy volunteers, intensity, expandability, and diversity of SARS-CoV-2 T-cell responses were profoundly reduced in patients with cancer, and the latter associated with a severe course of COVID-19. This identifies impaired SARS-CoV-2 T-cell immunity as a potential determinant for dismal outcome of COVID-19 in patients with cancer. SIGNIFICANCE: This first comprehensive analysis of SARS-CoV-2 immune responses in patients with cancer reports on the potential implications of impaired SARS-CoV-2 T-cell responses for understanding pathophysiology and predicting severity of COVID-19, which in turn might allow for the development of therapeutic measures and vaccines for this vulnerable patient population. See related commentary by Salomé and Horowitz, p. 1877 . This article is highlighted in the In This Issue feature, p. 1861 ., (©2021 American Association for Cancer Research.)- Published
- 2021
- Full Text
- View/download PDF
6. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition.
- Author
-
Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, Lübke M, Bauer J, Rieth J, Wacker M, Peter A, Hörber S, Traenkle B, Kaiser PD, Rothbauer U, Becker M, Junker D, Krause G, Strengert M, Schneiderhan-Marra N, Templin MF, Joos TO, Kowalewski DJ, Stos-Zweifel V, Fehr M, Rabsteyn A, Mirakaj V, Karbach J, Jäger E, Graf M, Gruber LC, Rachfalski D, Preuß B, Hagelstein I, Märklin M, Bakchoul T, Gouttefangeas C, Kohlbacher O, Klein R, Stevanović S, Rammensee HG, and Walz JS
- Subjects
- COVID-19 prevention & control, COVID-19 virology, Cross Reactions immunology, HLA-DR Antigens immunology, HLA-DR Antigens metabolism, Histocompatibility Antigens Class I immunology, Histocompatibility Antigens Class I metabolism, Humans, Immunologic Memory immunology, SARS-CoV-2 physiology, T-Lymphocytes metabolism, Viral Vaccines administration & dosage, COVID-19 immunology, Epitopes, T-Lymphocyte immunology, Peptides immunology, SARS-CoV-2 immunology, T-Lymphocytes immunology, Viral Vaccines immunology
- Abstract
T cell immunity is central for the control of viral infections. To characterize T cell immunity, but also for the development of vaccines, identification of exact viral T cell epitopes is fundamental. Here we identify and characterize multiple dominant and subdominant SARS-CoV-2 HLA class I and HLA-DR peptides as potential T cell epitopes in COVID-19 convalescent and unexposed individuals. SARS-CoV-2-specific peptides enabled detection of post-infectious T cell immunity, even in seronegative convalescent individuals. Cross-reactive SARS-CoV-2 peptides revealed pre-existing T cell responses in 81% of unexposed individuals and validated similarity with common cold coronaviruses, providing a functional basis for heterologous immunity in SARS-CoV-2 infection. Diversity of SARS-CoV-2 T cell responses was associated with mild symptoms of COVID-19, providing evidence that immunity requires recognition of multiple epitopes. Together, the proposed SARS-CoV-2 T cell epitopes enable identification of heterologous and post-infectious T cell immunity and facilitate development of diagnostic, preventive and therapeutic measures for COVID-19.
- Published
- 2021
- Full Text
- View/download PDF
7. Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups
- Author
-
Rammensee, Hans-Georg, Gouttefangeas, Cécile, Heidu, Sonja, Klein, Reinhild, Preuß, Beate, Walz, Juliane Sarah, Nelde, Annika, Haen, Sebastian P., Reth, Michael, Yang, Jianying, Tabatabai, Ghazaleh, Bösmüller, Hans, Hoffmann, Helen, Schindler, Michael, Planz, Oliver, Wiesmüller, Karl-Heinz, and Löffler, Markus W.
- Subjects
adjuvant ,lipopeptide ,SARS-CoV-2 ,peptide vaccine ,COVID-19 ,Medicine ,high-risk patient ,Article - Abstract
We describe the results of two vaccinations of a self-experimenting healthy volunteer with SARS-CoV-2-derived peptides performed in March and April 2020, respectively. The first set of peptides contained eight peptides predicted to bind to the individual's HLA molecules. The second set consisted of ten peptides predicted to bind promiscuously to several HLA-DR allotypes. The vaccine formulation contained the new TLR 1/2 agonist XS15 and was administered as an emulsion in Montanide as a single subcutaneous injection. Peripheral blood mononuclear cells isolated from blood drawn before and after vaccinations were assessed using Interferon-γ ELISpot assays and intracellular cytokine staining. We detected vaccine-induced CD4 T cell responses against six out of 11 peptides predicted to bind to HLA-DR after 19 days, following vaccination, for one peptide already at day 12. We used these results to support the design of a T-cell-inducing vaccine for application in high-risk patients, with weakened lymphocyte performance. Meanwhile, an according vaccine, incorporating T cell epitopes predominant in convalescents, is undergoing clinical trial testing.
- Published
- 2021
8. Defibrotide for the treatment of PIMS-TS in two pediatric patients
- Author
-
Lang, Peter, Eichholz, Thomas, Bakchoul, Tamam, Streiter, Monika, Petrasch, Maurice, Bösmüller, Hans, Klein, Reinhild, Rabsteyn, Armin, Lang, Anne-Marie, Adams, Constantin, Klingel, Karin, Gessner, Michaela, Rosenberger, Peter, Ruef, Peter, and Handgretinger, Rupert
- Subjects
Adolescent ,Fever ,SARS-CoV-2 ,Brief Report ,T-Lymphocytes ,Pneumonia, Viral ,COVID-19 ,defibrotide ,Blood Coagulation Factors ,Systemic Inflammatory Response Syndrome ,endotheliitis ,Abdominal Pain ,Betacoronavirus ,AcademicSubjects/MED00290 ,Polydeoxyribonucleotides ,children ,Humans ,complement ,Female ,AcademicSubjects/MED00670 ,Child ,Coronavirus Infections ,Pandemics ,Platelet Aggregation Inhibitors - Abstract
The pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 infection is a severe complication of coronavirus disease 2019. Since impaired coagulation and thrombosis/endotheliitis are suspected pathomechanisms, we treated 2 patients with defibrotide, a profibrinolytic, antithrombotic, antiinflammatory oligonucleotide. Symptoms resolved during treatment. Moreover, coagulation parameters indicating hypofibrinolysis and complement activation normalized. The pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 infection is a severe complication of coronavirus disease 2019. Since impaired coagulation and thrombosis/endotheliitis are suspected pathomechanisms, 2 patients received defibrotide, a profibrinolytic, antithrombotic, antiinflammatory oligonucleotide. Symptoms resolved and hypofibrinolysis/complement activation normalized during treatment.
- Published
- 2020
9. COVID-19 in Autoinflammatory Diseases with Immunosuppressive Treatment.
- Author
-
Welzel, Tatjana, Samba, Samuel Dembi, Klein, Reinhild, van den Anker, Johannes N., Kuemmerle-Deschner, Jasmin B., and Demirkaya, Eugen Feist; Eugen Feist; Erkan
- Subjects
COVID-19 ,THERAPEUTICS ,CRYOPYRIN-associated periodic syndromes ,FAMILIAL Mediterranean fever ,COVID-19 pandemic ,AUTOINFLAMMATORY diseases - Abstract
COVID-19 disease increases interleukin (IL)-1β release. Anti-IL-1-treatment is effective in IL-1-mediated autoinflammatory diseases (AID). This case series presents COVID-19 in patients with IL-1-mediated and unclassified AID with immunosuppressive therapy (IT). Patient 1 is a 34-year-old woman with an unclassified AID and methotrexate. Patients 2 and 3 (14-year-old girl and 12-year-old boy, respectively) have a Cryopyrin-Associated Periodic Syndrome (NLRP3 p.Q703K heterozygous, CAPS) treated with canakinumab 150 mg/month since three and five years, respectively. Patient 4 is a 15-year-old girl who has had familial Mediterranean fever (MEFV p.M694V homozygous) for 3 years treated with canakinumab 150 mg/month and colchicine. All patients had a mild acute COVID-19 course, particularly the adolescent patients. A few weeks after COVID-19 recovery, both CAPS patients developed increased AID activity, necessitating anti-IL-1-treatment intensification in one patient. At day 100, one out of four patients (25%) showed positive antibody response to SARS-CoV-2. This is one of the first reports providing follow-up data about COVID-19 in AID. The risk for severe acute COVID-19 disease was mild/moderate, but increased AID activity post-COVID-19 was detected. Follow-up data and data combination are needed to expand understanding of COVID-19 and SARS-CoV-2 immunity in AID and the role of IT. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.